End in Medical Technology

Labopharm files New Drug Submission with Health Canada for novel antidepressant

... (HAMD-17) total score from baseline to the end of the study in the trazodone group versus the ... of 0.012). The majority of the secondary efficacy end points, including the HAMD-17 depressed mood ... versus placebo in all three quality of sleep end points, with an improvement by the first week of ...

Spherix Announces Positive Phase 2 Study Results

... triglycerides of the patients by -59 mg/dl by the end of the first month on therapy, a decrease from baseline that remained at -41 mg/dl by the end of the 6 months of the trial. Naturlose also decreased serum LDL by an average -13 mg/dl by the end of the first month on therapy, while serum HDL ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... and completing our NDA submission by the end of the year." Safety and Tolerability ... DM is expected to complete enrollment around the end of June and is evaluating 10 mg of lorcaserin ... at baseline, at month 6, and at the end of the study to assess heart valve function over ...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding 2 log10 (>99%) ... ANA598, viral load was still declining at the end of the three days of treatment. Genotype 1b ... none of the patients receiving placebo showing an end of treatment response greater than 0.2 log10 ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... (patients who were HCV-RNA positive at the end of a minimum 12 weeks of treatment) and prior relapsers (patients who were HCV-RNA negative at the end of treatment and subsequently relapsed after ... of undetectable HCV-RNA at 24 weeks after the end of treatment. (2) EPIC3 (Evaluation of ...

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults

... that the presence of the advanced glycation end product (A.G.E.) called carboxymethyl-lysine ... protein is described as an Advanced Glycation end Product (A.G.E.). These damaged proteins are ... a proposed breaker of advanced glycation end products (A.G.E.s) for the treatment of systolic ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... the company expects to complete enrollment at the end of the first calendar quarter of 2009. ... enrollment of clevudine registration trials end of first quarter of 2009 -- File IND for PSI-7851 in first quarter of 2009 -- Report end of treatment data from 28 day add-on study with ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... recurrent venous thromboemolism at the end of six months of therapy. A final ... inhibiting activity of idrabiotaparinux. At the end of the initial six-month treatment with ... received avidin and 18 received placebo). At the end of the 30- minute infusion of avidin, mean ...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... therapeutic programs for HIV/AIDS before the end of 2008. "We are very pleased by the ... updated guidance on its expectations of 2008 year end cash to $60M in cash and cash equivalents, which ... -- Sangamo estimates that it expects to end 2009 with approximately $40M in cash and cash ...

NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study

... of anti-inflammatory agents, which is nearing the end of phase 3 clinical development for the treatment ... with hypertension and OA (112) before the end of 2008, in addition to the results of the ... monitoring was conducted at baseline and at the end of each three-week dose escalation (i.e. at ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... the SVR rate was 74 percent at 12 weeks after the end of treatment (SVR 12) in patients who received 4 ... the SVR rate was 56 percent at 24 weeks after the end of treatment (SVR 24) in patients who received ... of undetectable HCV-RNA at 24 weeks after the end of treatment. Per protocol, if a patient does not ...

Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma

... to work right away (P less than or equal to .004; end of week 1).(1) Similar results (P<.001) were ... in Study 1 [P=.073]).(1) The results seen at the end of treatment were similar to those demonstrated ... were recorded in an electronic diary at the end of weeks one through 12:(1) They included: during ...

Bronchitol Cystic Fibrosis Dose Trial Results Positive

... cystic fibrosis. The trial achieved its primary end point of demonstrating a dose dependent ... that can be forcibly exhaled in 1 second). At the end of the two-week Bronchitol treatment periods, ... Commercial partners None Primary end points: Change in FEV1 8.6% increase ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... Successful end of Phase 2 Meeting with the FDA for the Fabry ... 2 development. We also successfully completed an end of Phase 2 meeting with the FDA related to our ... announced that it had successfully completed an end of Phase 2 meeting for Amigal with the U.S. Food ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... time period, with follow-up assessments at the end of the 24-hour study period. Side effects were ... release initial results of this trial before the end of September 2008. A second Phase 3 clinical ... time period, with follow-up assessments at the end of the 24-hour study period. Side effects will be ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... arms of the study, SVR at 24 weeks after the end of treatment (SVR 24) was 56 percent and 55 ... of undetectable HCV-RNA at 24 weeks after the end of treatment. Per protocol, if a patient does not ... HCV-RNA in plasma at 12 weeks after the end of treatment. The protocol specified primary ...

Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of 'Start Clean' Strategy

... Reporting of HAIs in all 76 Public Hospitals by end of 2009 SUNNYVALE, Calif., July 28 ... of Healthcare Associated Infections (HAIs) by the end of 2009, according to the timelines published in ... underway and are expected to be complete by the end of 2008. This may lead to the rollout of a ...

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering

... been FDA approved for other indications such as end organ disease or other hypertension related ... smaller W/L ratios (11%). At the end of the study the W/L ratio in the olmesartan ... study, titled "Olmesartan Reducing Incidence of end stage renal stage in diabetic Nephropathy Trial," ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... 2008. -- First Phase 3 data available before the end of 2008 (from ACHIEVE 2/3, the trial in ... Phase 3 trial, BLISS-76, is expected by the end of summer 2008. The LymphoStat-B BLISS program is ... LymphoStat-B in patients with active SLE, by the end of summer 2008. -- First Phase 3 data ...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

... or who were viral negative at end of peginterferon and ribavirin therapy, but did ... virologic response at 12 weeks after the end of treatment (SVR 12) was 57 percent (ITT).(3-5) ... of undetectable HCV-RNA at 24 weeks after the end of treatment. Per protocol, if a patient ...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

... seven and 14 of the treatment periods, and at the end of the study. Follow-up calls with patients a further seven days after the end of the study were conducted to assess the ... similar over time, and naltrexone levels at the end of each treatment period below a quantifiable ...

Neurocrine Biosciences Reports First Quarter 2008 Results

... million, respectively. The Company expects to end 2008 with in excess of $100 million in cash and ... Company was scheduled to meet with the FDA for an end of review meeting following the December 12, 2007 ... due to internal FDA scheduling conflicts. The end of review meeting has been rescheduled by the FDA ...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

... response at 12 weeks after the end of treatment (SVR 12) was 57 percent (ITT).(1-3) ... HCV-RNA in plasma at 12 weeks after the end of treatment. The protocol specified primary ... HCV-RNA in plasma at 24 weeks after the end of treatment. 2 Intention-To-Treat (ITT) ...

Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)

... and significantly lower relapse rates after the end of treatment than Pegasys and Copegus combination ... percent, respectively).(5) -- Relapse after the end of treatment was lower for patients in ... 1.5 mcg regimen (p-value equal to 0.012). -- end of treatment response was higher in the Pegasys ...

Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

... outcome of this Study. While this represents the end of one chapter for Keryx, it is not the end of Keryx. Drug development is inherently risky ... our Zerenex high-dose Phase 2 trial before the end of the year." The Company will host a ...

Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status

... of its first AZ-004 Phase 3 clinical trial by the end of Q1 2008. "This is a transitional year for ... the second half of 2007, Alexza conducted an end of Phase 2 meeting with the FDA and completed ... data analysis is expected to be completed by the end of Q1 2008. These data, along with the data ...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

... producing a 100 percent complete remission at end of treatment with an estimated 89 percent ... consolidation, 100 percent obtained a CR at the end of treatment. With a median follow up of 20 ... for subsequent Zevalin, 100% obtained a CR at the end of treatment. With a median follow up of 20 ...

Schering-Plough Reports Top-Line Results of the IDEAL Study

... with both PEGINTRON regimens relapsed after the end of treatment compared to those receiving Pegasys ... 41 percent, respectively). Importantly, while end of treatment response was higher in the ... combination therapy relapsed after the end of treatment (24 vs. 20 vs. 32 percent, ...

Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study

... improvement, from the baseline assessment at the end of the 12-week treatment period. The ACR ... of patients who were ACR 20 responders at the end of week 12. Secondary efficacy endpoints were ACR ... as well as Disease Activity Score (DAS) at the end of week 12. R788 and RA RA is a progressive, ...

Interview of the Vice President

... and how Democrats have sort of handled their end of negotiating with you guys, whether it's ... still got 11 pending. And here we are at the end of the calendar year, well into the new fiscal ... of the next year. Now, where exactly we'll end up a year from now is going to be based on ...

Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout

... deep product pipeline," stated Dr. Quart. "By the end of this year, we hope to have four novel ... the clinic for three distinct indications by the end of 2007, with an additional ... the clinic for three distinct indications by the end of 2007, with an additional ...

Vanda Pharmaceuticals Reports Third Quarter 2007 Results

... of $0.1 million. -- The balance sheet at the end of the third quarter of 2007 reflected $109.4 ... shares of common stock outstanding at the end of the year. CONFERENCE CALL The company has ... 21,012,815 Cash and cash equivalents, end of period ...

38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty

... to demonstrate the political will required to end the scourge of poverty once and for all." For 24 ... servicing to eradicate poverty and at the end 1000 candles were lit to express solidarity ... the world's leaders to meet their promises to end poverty and inequality. In particular, ...

INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients

... five days into therapy and continued through the end of the two-week study period, according to ... were more likely to require doses near the upper end of the recommended ranges to control their ... total change in PANSS score from baseline to the end of the monotherapy phase (day 14). The average ...

Microlife's Home Blood Pressure Monitors Proven Accurate Even for Critical Patients

... Proven Accuracy (Severe arterial-sclerosis in end Stage Renal Disease) DUNEDIN, Fla., Oct. 2 ... in patients with severe arterial-sclerosis in end Stage Renal Disease (ESRD). The study, led by ... According to Professor Pickering, "Patients with end Stage Renal Disease have very stiff arteries, and ...

DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study

... were classified as drug compliant. At the end of this eight-week study, the mean difference in ... a reversible drug-related effect at the end of the one-week wash-out period. "There is a ... (~23% reduction), was maintained at the end of the DOV 21,947 treatment period (~29% ...

Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc

... with our product a step closer to patients with end stage blood cancer. Reviroc shares its ... label study 25 patients, each of whom had reached end stage Non-Hodgkin's lymphoma, were treated in ... from autologous transplants for patients with end stage blood cancer. An autologous transplant uses ...

Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

... marketable securities were $103.9 million at the end of the second quarter. Nabi has completed the ... Phase I trial; study completion expected by end of 2007 Upcoming Milestones Nabi is currently ... second quarter of the prior year due to increased end user demand and sales of Nabi-HB. Nabi Biologics ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... and efficacy findings; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of partnered products may be ... ------- ------ Cash and cash equivalents at end of period $114,992 $31,829 ...

John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden

... Millennium Villages in Ghana and Tanzania. The non-profit's mission is to end poverty around the world through sustainable development at the ... targets and disburses money in response to proven results. At the end of 2008, programs supported by the Global Fund have averted more than 3.5 ...